AI and Protocol Design in Clinical Trials: A Strategic Briefing

The Strategic Bottleneck 

For pharmaceutical executives, CRO leaders, and hospital administrators, the central clinical development bottleneck is no longer simply whether enough potential participants exist in the global population. Instead, the crisis lies in whether clinical trials are designed, activated, and managed so that the right patients can be identified and enrolled without overwhelming research sites or eroding patient trust. 

The industry is currently facing a massive failure rate in trial recruitment. Systematic reviews reveal that approximately 80% of clinical trials fail to meet their initial enrollment targets and timelines, resulting in costly downstream delays. Furthermore, data indicates that 53% of studies experience extended enrollment timelines, 41% of activated sites under-enroll, and roughly one in six enrolled volunteers drop out before the study's completion.

A core driver of this crisis is the pervasive "Field of Dreams" fallacy in clinical research: the passive assumption that if a sponsor simply designs a scientifically rigorous protocol and opens a site, patients will automatically appear. This mindset treats recruitment as a downstream marketing or site-performance issue rather than addressing the root cause. A protocol can be scientifically sound and statistically robust, yet still fail entirely once it encounters the realities of actual clinical practice. Recruitment is not an executional afterthought; it is a systemic protocol and operational failure that is embedded months, or even years, before the first patient is ever screened.

The Disconnect Between Idealized Protocols and Operational Reality 

The main reason it’s so hard to find patients today is because of how study rules are written. In trying to make the science perfectly exact, researchers have made the trials far too complicated for real people. Studies in precision oncology, immunology, and rare diseases increasingly combine stringent biomarker criteria, rigid prior-line constraints, specific washout periods, and demanding imaging schedules. While these parameters look optimal from a statistical perspective, there is a profound disconnect between the idealized protocol and real-world operational feasibility.

At the site level, this complexity translates into a crushing administrative burden. Research coordinators are forced into highly manual, labor-intensive chart reviews, often needing to screen dozens of complex patient records just to identify a single eligible candidate. Coordinators do not experience a trial as a sophisticated strategic asset; they experience it as the practical challenge of managing screening logs, navigating visit complexities, and handling massive screen failure rates.

When these unrealistic assumptions clash with clinical reality, the result is disastrous for study timelines and budgets. An estimated 76% of clinical trials go through at least one major protocol amendment, with each amendment adding months of delay and significant extra costs. These amendments are rarely driven by new scientific discoveries; rather, they are the result of misinformed design choices, restrictive eligibility criteria, and underestimated site burdens that only become apparent once execution begins and screen failures mount.

The Role of AI in Stress-Testing and Protocol Feasibility 

To stop building trials that look perfect on paper but trigger a cascade of costly delays the moment they reach the clinic, the industry must treat real-world patient enrollment as the bedrock of protocol design, rather than relying on desperate, downstream rescue efforts. This is where Artificial Intelligence fundamentally (AI) alters the landscape. For example, Natural Language Processing (NLP) and Large Language Models (LLMs) are now being used to ingest and parse complex, unstructured eligibility criteria directly from draft protocols.

Before a protocol is finalized and resources are committed, AI-enabled feasibility models can stress-test the study design against real-world parameters. These models compare the parsed trial criteria against massive datasets of de-identified Electronic Health Record (EHR) data, claims-derived cohorts, and disease registries. This simulation estimates likely screen failure drivers, site catchment overlap, and actual patient visit burdens before the operational damage is done.

The strategic value of this approach lies in identifying where protocol constraints needlessly exclude patients. For instance, an AI model can reveal if a specific laboratory threshold, mandatory on-site biopsy, or prior-therapy requirement is aggressively filtering out otherwise clinically appropriate candidates. AI does not replace scientific judgment, but it exposes the real-world impact of clinical assumptions, making trade-offs visible early. By identifying these flaws during the design phase, clinical, biostatistics, and regulatory teams can make data-driven trade-offs, adjusting overly restrictive criteria and entirely preventing avoidable, expensive protocol amendments.

Shifting to an Active, AI-Driven Engagement Model 

Moving from the design phase to execution requires a shift from passive centralized planning to decentralized, active intelligence at the site level. Where the traditional model relies on static documents and fragmented systems, AI enables a dynamic, continuous loop of learning and predictability.

The most advanced real-world example of this shift is connecting AI directly to electronic health record systems to automatically review patient charts. While health systems hold vast amounts of unstructured data in physician notes, pathology reports, and imaging impressions, NLP systems can seamlessly convert that unstructured content into instant candidate matches. This capability instantly transforms weeks of manual chart hunting into a screen-ready list for authorized site staff, drastically reducing the manual pre-screening workload that currently paralyzes research coordinators.

However, scaling this active engagement model requires rigorous adherence to data governance and regulatory compliance. Global regulators, including the FDA and EMA, mandate that AI applications in clinical trials demonstrate clear contexts of use, human-centric design, and robust performance monitoring. Integrating AI with EHRs requires strict HIPAA compliance, privacy-preserving data partnerships, and clear rules for patient re-identification. AI-generated matches must function as transparent decision-support tools—where coordinators can audit the source data and confidence scores—ensuring that final eligibility determinations remain firmly in the hands of qualified clinical personnel.

The Future of Trial Execution 

To overcome the recruitment crisis and safely bring AI into the clinic, the industry is using Trially to eliminate these everyday obstacles. Trially’s HIPAA-compliant AI platform deploys powerful LLM agents that integrate directly with EHR systems to instantly match patients to complex trials with roughly 95% accuracy. By bridging the gap between protocol design and site-level realities, Trially eliminates the guesswork that leads to "Field of Dreams" failures, drastically reducing screen failure rates by 73%. Furthermore, the platform saves clinical sites hundreds of hours a month by automating exhaustive manual chart reviews. By providing exact, data-backed patient feasibility counts and automating pre-screening workflows, Trially transforms clinical research from a passive, delayed process into a high-speed, predictable operational reality.

End Notes

Source: "AI-Driven Clinical Trial Recruitment and Design" is a 20 minute audio interview and comprehensively outlines how clinical trial recruitment is a systemic operational failure—with 80% of trials missing initial enrollment targets—rather than a mere marketing issue. It details how Artificial Intelligence and NLP models can parse complex precision medicine criteria to stress-test protocols, using examples like identifying how restrictive lab thresholds drive screen failures to make trade-offs visible early and prevent costly amendments. Furthermore, NLP systems can convert unstructured clinical notes into screen-ready candidate matches, significantly relieving the manual chart-screening burden placed on Clinical Research Coordinators. However, the source strongly emphasizes that AI should serve strictly as auditable decision support, with qualified human personnel making the final determinations. Scaling these AI solutions requires adherence to FDA and EMA guidelines that focus on human-centric design, clear contexts of use, rigorous risk assessment, and traceable data lineage. Ultimately, the successful economics and deployment of AI rely on privacy-preserving data partnerships compliant with HIPAA, IRB, and GCP standards, with the overarching goal of making clinical sites more productive rather than replacing them.

Source: "AI Can Help Design Better Trials But It Still Can't Tell You Whether Patients Will Join Them". This source cautions against the dangerous assumption that an AI-optimized protocol will automatically translate into a recruitable trial, highlighting the vast disconnect between theoretical design and real-world patients. It argues that the ability to recruit must be an upfront design consideration rather than a downstream operational problem, noting that a trial that cannot recruit is not practically a "better" trial at all. Furthermore, it illustrates that patients and research sites do not experience a trial as a sophisticated scientific document, but rather as tangible burdens involving time, disruption, and competing workloads. This includes the practical challenges that site coordinators face in explaining and managing complex study expectations—human realities that AI design teams frequently miss. Ultimately, the source advises the industry to resist treating recruitment as merely a downstream marketing or execution activity, emphasizing instead that enrollment success is heavily dictated by systemic design decisions made months or years earlier. 

Source: How Deep Learning Is Changing Clinical Trial Design, Execution, And Analysis In 2026 .  Mentions that text-to-protocol AI matching interprets unstructured clinical notes to automate chart review and reduce the manual workload of participant recruitment.

Source: "Aligning AI Use Clinical Trials With FDA And EMA Expectations". Context: Discusses how EMA and FDA expectations require AI used in clinical trials to maintain data integrity, transparency, and clinical oversight.  Refers to the joint FDA/EMA Guiding Principles of Good AI Practice intended to align international expectations for responsible AI use in drug development.

Source: "How AI is Unlocking Smarter Clinical Trial Protocols - MedCity News". Context: Provides the statistic from Tufts CSDD that 76% of trials experience at least one major protocol amendment, adding months of delay. Explains that static protocols force reactive, iterative mitigations and that massive amendments are caused by misaligned criteria and restrictive operational workflows.  Highlights how digital protocol intelligence helps avoid designing studies from scratch and reduces the likelihood of costly amendments through evidence-based forecasting.

Source: Trially

• Compliance: It is a HIPAA-compliant AI platform that helps researchers quickly find, match, and enroll the right patients for their clinical trials by automatically scanning medical records and reaching out to potential candidates.

• Core Technology: It deploys Large Language Model (LLM) agents that integrate directly with Electronic Health Record (EHR) systems.

• Matching Accuracy: It instantly matches patients to complex clinical trials with roughly 95% accuracy.

• Screen Failure Reduction: It reduces trial screen failure rates by 73%.

• Time Savings: It saves clinical sites hundreds of hours a month by automating exhaustive manual chart reviews.

• Feasibility & Workflow: It provides exact, data-backed patient feasibility counts and automates pre-screening workflows.